Immunome, Inc. (IMNM)
NASDAQ: IMNM · Real-Time Price · USD
6.62
-0.37 (-5.29%)
Mar 31, 2025, 1:43 PM EDT - Market open

Immunome Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019 - 2018
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019 - 2018
Revenue
9.0414.02---
Upgrade
Revenue Growth (YoY)
-35.50%----
Upgrade
Cost of Revenue
129.5423.0923.11--
Upgrade
Gross Profit
-120.5-9.07-23.11--
Upgrade
Selling, General & Admin
32.9619.6613.7911.094.78
Upgrade
Research & Development
---14.117.49
Upgrade
Operating Expenses
32.9619.6613.7925.212.26
Upgrade
Operating Income
-153.46-28.73-36.9-25.2-12.26
Upgrade
Interest Expense
----0.01-0.04
Upgrade
Interest & Investment Income
12.842.720.01--
Upgrade
Other Non Operating Income (Expenses)
-----5.54
Upgrade
EBT Excluding Unusual Items
-140.62-26-36.9-25.21-17.84
Upgrade
Other Unusual Items
---0.5-
Upgrade
Pretax Income
-292.96-106.81-36.9-24.71-17.84
Upgrade
Net Income
-292.96-106.81-36.9-24.71-17.84
Upgrade
Preferred Dividends & Other Adjustments
--0.62--
Upgrade
Net Income to Common
-292.96-106.81-37.52-24.71-17.84
Upgrade
Shares Outstanding (Basic)
592012123
Upgrade
Shares Outstanding (Diluted)
592012123
Upgrade
Shares Change (YoY)
195.51%63.64%5.10%240.41%209.85%
Upgrade
EPS (Basic)
-5.00-5.38-3.09-2.14-5.26
Upgrade
EPS (Diluted)
-5.00-5.38-3.09-2.14-5.26
Upgrade
Free Cash Flow
-164.3-8.4-28.94-18.31-12.72
Upgrade
Free Cash Flow Per Share
-2.80-0.42-2.39-1.59-3.75
Upgrade
Gross Margin
--64.71%---
Upgrade
Operating Margin
-1697.33%-204.94%---
Upgrade
Profit Margin
-3240.38%-761.92%---
Upgrade
Free Cash Flow Margin
-1817.30%-59.92%---
Upgrade
EBITDA
-151.89-28.27-36.48-24.45-11.51
Upgrade
EBITDA Margin
--201.68%---
Upgrade
D&A For EBITDA
1.570.460.420.760.76
Upgrade
EBIT
-153.46-28.73-36.9-25.2-12.26
Upgrade
EBIT Margin
--204.94%---
Upgrade
Updated Mar 19, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q